Platelet Function in Patients With an Acute Coronary Syndrome (ATLANTIS-ACS)
|ClinicalTrials.gov Identifier: NCT01992484|
Recruitment Status : Unknown
Verified November 2013 by Jolanta Siller-Matula, Medical University of Vienna.
Recruitment status was: Recruiting
First Posted : November 25, 2013
Last Update Posted : November 25, 2013
The aims of the study are to:
- explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome
- investigate whether a therapeutic window exist for novel platelet inhibitors
- investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario
- investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome
- investigate synergistic effects between aspirin and novel platelet inhibitors
|Condition or disease|
|Acute Coronary Syndrome (ACS)|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||June 2015|
- Net clinical benefit. [ Time Frame: 1 year ]A composite of MACE and BARC=>2 bleedings.
- MACE and Major bleeding [ Time Frame: 1 year ]
MACE: the composite of stent thrombosis, cardiac death and myocardial infarction.
Major Bleeding: BARC =>2, TIMI major, GUSTO moderate-severe-life threatening.
- single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke. [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01992484
|Contact: Jolanta M Siller-Matula, PD MD PhD||0043 1 email@example.com|
|Medical Univerity of Vienna, Department of Cardiology||Recruiting|
|Principal Investigator: Jolanta M Siller-Matula, PD MD PhD|
|Principal Investigator: Georg Delle-Karth, MD|